Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (48142)	5/29/2012 10:57:10 AM
From: Paul Senior	Read Replies (2) \| Respond to of 78740

LEY.pa looks good to me. I'll add to my watch list.

To: Spekulatius who wrote (48142)	5/31/2012 12:22:26 AM
From: Jurgis Bekepuris	Respond to of 78740

LEY.PA looks good.

To: Spekulatius who wrote (48142)	5/31/2012 8:46:12 AM
From: Ditchdigger	Respond to of 78740

Thanks Clownbuck, will check out LEY.PA when I get some time. I see GSK is getting even more hostile, now trying to toss the board of HGSI out. GlaxoSmithKline may try to oust Human Genome board, Reuters reports Baltimore Business JournalDate: Thursday, May 31, 2012, 7:07am EDT GlaxoSmithKline PLC is readying a bid to clean house at Human Genome Sciences Inc.'s board of directors and pack the board with hand-picked nominees, according to a report Wednesday from Reuters. As part of its $2.6 billion takeover attempt of the Rockville biotech, GSK "has started reaching out to executives in the pharmaceutical industry as well as finance and governance experts" who could serve on HGS's board, Reuters reported based on anonymous sources. Those sources also told Reuters that GSK may extend its offer beyond the June 7 deadline.